[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Queen Mary Hospital, Hong Kong\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":205},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,44,74,102,129,155,177],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100628394","hifu-vs-observation-for-lsil-of-cervix-a-randomized-controlled-trial-100628394",false,"NCT07461064","HIFU vs Observation for LSIL of Cervix: A Randomized Controlled Trial","High-Intensity Focused Ultrasound (HIFU) Versus Observation for Low-Grade Squamous Intraepithelial Lesions of Cervix: A Randomized Controlled Trial","HIFU Colpo","Inclusion Criteria:\n\n1. Pre-menopausal women aged 18 years old or above.\n2. Women had satisfactory colposcopy for abnormal cervical smear with positive HR-HPV test, with histologically confirmed diagnosis of cervix LSIL or CIN1.\n\nExclusion Criteria:\n\n1. Women who are pregnant or breast feeding at the time of planned HIFU treatment.\n2. Women without HR-HPV, or previously treated for CIN or cervical cancer.\n3. Women not able to attend follow up.\n4. Women with evidence of acute genital tract infection.\n5. Women with significant autoimmune diseases, immunodeficiency diseases, severe cardiac, hepatic, renal, and coagulation dysfunctions.\n6. Women not able to give consent.\n\nParticipants be considered withdrawn from study or excluded from analysis\n\n1. Formally recruited into the study but withdraw from the study after randomization.\n2. Do not attend both follow-up appointments.","FEMALE","18 Years","55 Years",{"count":21,"type":22},180,"ESTIMATED","INTERVENTIONAL",[25],"NA","The majority of low-grade pre-invasive lesions of cervix (low-grade squamous intraepithelial lesions, LSIL).will regress spontaneously over 2 years and immediate treatment may not be necessary. According to the Hong Kong College of Obstetricians and Gynaecologists (HKCOG), if a low-grade lesion is confirmed by colposcopy and biopsy, the patient can be observed and followed up with HPV testing or co-testing at 12 months, irrespective of age. This randomized controlled study is to determine whether high-intensity focused ultrasound (HIFU) treatment of low-grade pre-invasive lesions of cervix, can cause regression of these lesions in more patients within a specific time when compared to observation as a standard management according to HKCOG Guidelines. All eligible patients will be randomized in a 1:1 ratio into 2 groups: high-intensity focused ultrasound (HIFU) or Observation group. Background information of the patients such as age, parity, body mass index, smoking status and the presence of chronic medical disease will be collected. All patients with cervical HR-HPV status will be tested. Patients randomized into HIFU group will receive HIFU treatment within 2 weeks after randomization. Those randomized into Observation group will have no intervention. All patients will attend follow-up at 6 and 12 months after randomization, during which cervical smear for cytology (with cytopathologists blinded to the treatment group) and HR-HPV testing will be performed. The rate of cytological LSIL regression and HR-HPV clearance rates at 6 and 12 months in both groups will be analyzed. Patients will be referred back to colposcopy clinic for repeat colposcopy if needed according to HKCOG Guidelines. At the 12-month follow-up visit, if referral to repeat colposcopy is not needed, patients will be referred back to their primary care physicians, Department of Health Family Health Service, Family Planning Association or other primary care centres for follow-up cervical smears.",[28,29],"HPV Disease","Cervical Intraepithelial Neoplasia Grade I",[31],"Cervical HR-HPV-related low-grade squamous intraepithelial lesion","NOT_YET_RECRUITING","2026-03-04",{"date":35,"type":36},"2026-03-10","ACTUAL",{"date":38,"type":22},"2026-05-01",{"date":40,"type":22},"2028-12-30",{"name":42,"class":43},"Queen Mary Hospital, Hong Kong","OTHER",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":51,"minAge":4,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":60,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},"100523425","dic-markers-and-thrombin-generation-parameters-in-patients-on-ecmo-support-a-pilot-study-100523425","NCT06095518","DIC Markers and Thrombin Generation Parameters in Patients on ECMO Support: a Pilot Study","DIC-ECMO","Inclusion Criteria:\n\n* Age ≧ 18; AND\n* Admitted to the mixed medical-surgical intensive care units of Queen Mary Hospital or Tuen Mun Hospital in Hong Kong; AND\n* Require either veno-arterial (VA) or veno-venous (VV) extracorporeal membrane oxygenation (ECMO) support.\n\nExclusion Criteria:\n\n* Patients who are on central VA-ECMO support; OR\n* Patients with missing clinical data; OR\n* Patients with pre-existing thromboembolism requiring long term anticoagulation prior to ECMO cannulation; OR\n* Post-operative admissions","ALL","80 Years",{"count":54,"type":22},50,"OBSERVATIONAL","To study the correlation between novel DIC markers and thrombin generation parameters with thrombotic and hemorrhagic complications of patients on ECMO support.",[58,59],"Extracorporeal Circulation; Complications","Extracorporeal Membrane Oxygenation Complication",[61,62,63],"ECMO","Thrombosis","Haemorrhage","RECRUITING","2025-07-21",{"date":67,"type":36},"2025-07-24",{"date":69,"type":36},"2023-05-30",{"date":71,"type":22},"2025-12-31",{"name":42,"class":43},1,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":82,"minAge":83,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":23,"phases":86,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":96,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":73},"100518962","pul-vs-turp-in-bph-patients-with-urinary-retention-100518962","NCT06037356","PUL vs TURP in BPH Patients With Urinary Retention","Prostatic Urethral Lift Versus Transurethral Resection of Prostate in Benign Prostatic Hyperplasia Patients With Urinary Retention","PULTUR","Inclusion Criteria:\n\n* Male patients\n* age \\>40 years old\n* urinary retention who failed trial without catheter\n\nExclusion Criteria:\n\n* Inability to provide consent OR no guardians or relatives to help provide consent on patient's behalf\n* Active urinary tract infection\n* Previous surgical treatment for benign prostatic hyperplasia (i.e., TURP, prostatic urethral lift, etc.)\n* Bladder stones\n* Urethral strictures or bladder neck contractures\n* Prostate size \\>100mL\n* Solely obstructing median lobe\n* Urinary retention not due to obstruction (i.e., Bladder outflow obstruction index \\\u003C20 on urodynamic studies)\n* Poor detrusor contractility (maximum detrusor pressure \\\u003C20cmH2O during voiding phase)\n* Anticoagulant or antiplatelet agents that cannot be stopped","MALE","40 Years",{"count":85,"type":22},100,[25],"The study will be a prospective, randomized controlled trial comparing prostatic urethral lift (PUL) versus transurethral resection of prostate (TURP) in benign prostate hyperplasia (BPH) patients with urinary retention. The primary objective of this study is to compare the catheter-free rates of PUL vs TURP. Secondary objectives include comparison of complications rates, cost effectiveness, patient satisfactory, symptom scores, quality of life measures and urodynamic parameters.",[89],"BPH With Urinary Obstruction",[91,92,93,94,95],"BPH","Urinary retention","prostatic urethral lift","PUL","TURP",{"date":67,"type":36},{"date":98,"type":36},"2025-01-01",{"date":100,"type":22},"2035-05-30",{"name":42,"class":43},{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":51,"minAge":18,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":23,"phases":111,"briefSummary":113,"conditions":114,"keywords":118,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":128,"locationsCount":73},"100565533","phase-3-efficacy-and-safety-of-add-on-timolol-for-egfr-tki-and-alk-tki-induced-paronychia-100565533","NCT06643416","Efficacy and Safety of Add-on Timolol for EGFR-TKI and ALK-TKI Induced Paronychia","Efficacy and Safety of Add-on Topical Timolol in the Management of Epidermal Growth Factor and Anaplastic Lymphoma Kinase Receptor Tyrosine Kinase Inhibitor-induced Paronychia: a Prospective Randomized Open-labelled Trial","Inclusion criteria\n\n1. Aged 18 years or above, either males or females.\n2. Received EGFR-TKI and ALK-TKI, namely gefitinib, erlotinib, afatinib, osimertinib, amivantamab, dacomitinib, mobocertinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib for the treatment of non-small cell lung cancer.\n3. Paronychia (fingernails, toenails, or both) as an adverse event from EGFR-TKI use\n4. Written informed consent obtained from patient\n5. Subjects are diagnosed with advanced non-small cell lung cancer\n\nExclusion criteria\n\n1. 1\\. Age below18\n2. 2\\. Patients who are allergic to, or contraindicated to topical timolol use\n3. 3\\. Pregnant women or nursing mother\n4. 4\\. Non-consenting patients\n5. 5\\. Subjects are not diagnosed with advanced non-small cell lung cancer",{"count":110,"type":22},40,[112],"PHASE3","To assess the clinical efficacy of add-on topical timolol 0.5% eye drops to betamethasone valerate 0.1% for the treatment of EGFR-TKI and ALK-TKI induced paronychia.",[115,116,117],"Paronychia","EGFR-TKI","ALK-TKI",[119,120,121,117],"EGFR TKI","paronychia","timolol","2024-10-16",{"date":124,"type":36},"2024-10-18",{"date":126,"type":22},"2024-10-09",{"date":71,"type":22},{"name":42,"class":43},{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":51,"minAge":18,"maxAge":136,"enrollmentInfo":137,"targetDuration":139,"studyType":55,"phases":4,"briefSummary":140,"conditions":141,"keywords":143,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":4},"100529799","safety-feasibility-and-clinical-utility-of-critical-care-transesophageal-echocardiography-in-hong-kong-100529799","NCT06178471","Safety, Feasibility and Clinical Utility of Critical Care Transesophageal Echocardiography in Hong Kong","SAFE-TEE","Inclusion Criteria:\n\n* Age ≧ 18; AND\n* Admitted to the mixed medical-surgical intensive care units of Queen Mary Hospital in Hong Kong; AND\n* Intubated for invasive mechanical ventilation; AND\n* Clinically indicated for transesophageal echocardiography (TEE)\n\nExclusion Criteria:\n\nPatient possessing absolute contraindication(s) to TEE examination according to the ASE guideline 2013:\n\n* Perforated viscus\n* Esophageal stricture\n* Esophageal tumor\n* Esophageal perforation\n* Esophageal laceration\n* Esophageal diverticulum\n* Active upper gastrointestinal bleed","100 Years",{"count":138,"type":22},200,"6 Months","Critical care echocardiography is increasingly recognized as an essential skill for intensivists to achieve during their training and fellowship. It serves to provide critical information to guide clinical management in patients with hemodynamic collapse and respiratory insufficiency. While transthoracic echocardiography (TTE) could be adequate for assessment in most situations, patient factors such as body habitus, presence of chest drains and tubes, presence of thoracic surgical dressings, requirement of high ventilatory support may impede operators from obtaining satisfactory images for evaluation. Moreover, operators in TTE require time and experience for adequate skill and technique acquisition. In specific pathologies such as infective endocarditis, presence of thrombus in left atrial appendage, and evaluation of intracardiac shunts, TEE has been shown to be superior to TTE for proper and accurate diagnosis. Therefore, TEE is widely accepted as the preferred and essential modality for echocardiographic examination especially in European countries. Countries such as France and North American have included critical care TEE as a core curriculum in the critical care training pathway.\n\nIn Hong Kong, only basic critical care echocardiography using TTE is required during training and in clinical practice. TEE evaluation is mostly performed in cardiac surgery units by cardiac anesthetists and in stable patients by cardiologists. Critical care TEE is seldom performed by intensivists independently for hemodynamic assessment and evaluation of cardiopulmonary failure. This study describes the safety, feasibility, and clinical utility of critical care TEE by critical care fellows in a university-affiliated institute providing tertiary care to the territory. With implementation of this essential technique in a single center, this study serves to act as a generalizable guidance to achieve an ultimate goal of incorporating this technique as core curriculum in critical care training in parts of the world where critical care TEE is not well established.",[142],"Cardiopulmonary Failure",[144,145,146],"Echocardiography","Transesophageal Echocardiography","Critical Care Echocardiography","2024-10-15",{"date":149,"type":36},"2024-10-17",{"date":151,"type":22},"2025-09-08",{"date":153,"type":22},"2027-07-01",{"name":42,"class":43},{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":51,"minAge":18,"maxAge":4,"enrollmentInfo":162,"targetDuration":4,"studyType":23,"phases":164,"briefSummary":166,"conditions":167,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":73},"100558455","phase-4-vitamin-d-replacement-in-bronchiectasis-100558455","NCT06551337","Vitamin D Replacement in Bronchiectasis","Prospective Clinical Study on Vitamin D Replacement in Bronchiectasis - A Pilot Study","Inclusion Criteria:\n\n1. ages 18 years or above, male or female.\n2. confirmed diagnosis of non-CF bronchiectasis based on high-resolution computed tomography (HRCT) scan.\n3. participation in the prior study entitled \"Prospective clinical study on serum 25-hydroxyvitamin D (25-OH D) level and risk of bronchiectasis exacerbation\" (UW 22-317)\n\nExclusion Criteria:\n\n1. underlying asthma, COPD and other co-existing respiratory diseases\n2. underlying osteoporosis\n3. supplementary Vitamin D in their regimen\n4. advanced chronic kidney disease with estimated glomerular filtration rate (eGFR) \\\u003C 30mL\u002Fmin",{"count":163,"type":22},104,[165],"PHASE4","This study seeks to address the limitations in previous related studies on vitamin D replacement and bronchiectasis exacerbation occurrence through a self-controlled pilot study. The investigators aim to investigate whether vitamin D replacement in bronchiectasis patients with vitamin D deficiency can reduce hospitalized bronchiectasis exacerbation occurrence. Patients who participated in the prior study entitled \"Prospective clinical study on serum 25-hydroxyvitamin D (25-OH D) level and risk of bronchiectasis exacerbation\" (UW 22-317) will be invited for participation during regular clinic follow-up and management in Queen Mary Hospital. If participants are willing to join the further research, participants will be recruited in this self-controlled study. There are some differences from usual management to non-CF bronchiectasis subjects. The study subjects would be checked for their blood 25-hydroxyvitamin-D level during the study period. The non-CF bronchiectasis subjects with Vitamin D deficiency would be given 1000 IU and 2000 IU (if needed). The investigators aim to correct their Vitamin D deficiency completely, aiming at blood 25-hydroxyvitamin-D level \\>=50, i.e. treat to target. The dose depends on the level of Vitamin D after replacement. If blood 25-hydroxyvitamin-D level is 50 or above, then 1000 IU is suffice. If blood 25-hydroxyvitamin-D level is still below 50, the investigators will increase to 2000 IU.",[168],"Bronchiectasis","2024-08-09",{"date":171,"type":36},"2024-08-13",{"date":173,"type":36},"2024-04-17",{"date":175,"type":22},"2027-06-30",{"name":42,"class":43},{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":4,"eligibilityCriteria":183,"healthyVolunteers":11,"sex":51,"minAge":18,"maxAge":4,"enrollmentInfo":184,"targetDuration":4,"studyType":23,"phases":186,"briefSummary":187,"conditions":188,"keywords":192,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":73},"100232038","eswl-for-distal-ureteric-stone-supine-versus-prone-100232038","NCT02298465","ESWL for Distal Ureteric Stone: Supine Versus Prone","Randomized Controlled Study on Extracorporeal Shockwave Lithotripsy for Distal Ureteric Stone: Transgluteal Versus Traditional Prone Approach","Inclusion Criteria:\n\n* All patients, over 18 years of age, with distal ureteric stones with stone size of ≥3mm on kidney-ureter-bladder (KUB) X-ray who opted for ESWL treatment\n\nExclusion Criteria:\n\n* Patients who are unable to provide consent\n* radiolucent stones\n* active urinary tract infections\n* pregnancy\n* uncontrolled hypertension\n* uncontrolled bleeding tendencies\n* severe skeletal malformations\n* arterial aneurysms within the vicinity of the stone (such as iliac artery aneurysms)\n* unable to assume the appropriate position (prone or supine) for ESWL\n* solitary kidneys\n* transplanted kidneys\n* presence of ureteric stents",{"count":185,"type":22},130,[25],"Extracorporeal shockwave lithotripsy (ESWL) for urinary stone is common and widespread nowadays. Approximately 80% of urinary stones are treated by ESWL. Traditionally distal ureteric stones are treated with ESWL in the prone position. However, as some patients cannot tolerate lying in the prone due to medical illness such as chronic obstructive pulmonary disease (COPD), some authors have reported using the supine approach of ESWL for treatment of distal ureter stones. No serious complications had developed in the patients who underwent supine approach. Only minor complications such as self-limiting blood in the urine, painful passage of urine, or local pain that had responded to oral painkillers. There were no serious complications encountered in children as well. In the most recent retrospective review by Tolley et al, they had revealed that patients who had underwent supine ESWL for distal ureteric stones had an improved stone-free rate compared with the traditional prone approach.\n\nPatient with radio-opaque distal ureteric stones (stones below the sacroiliac joint) on KUB X-ray, who have opted for ESWL treatment, are randomized into two groups: one undergoing ESWL in the supine position and the other undergoing ESWL in the prone position. Patients will be observed for two hours after ESWL before being discharged. Oral painkillers as necessary will be provided to the patient. The patients will have a KUB Xray at 2 weeks post-ESWL, and then monthly afterwards if required. If there are residual stones at the 2-week follow-up, the patient will be offered ESWL again. Patients are free to withdraw from the study at any time and will continue to be managed as per usual.\n\nThe investigators aim to have 130 patients, with 65 patients in each group with an interim analyses to be performed when 66 patients have been recruited (33 patients in each group).",[189,190,191],"Urinary Tract Stones","Urinary Stones","Urinary Calculi",[193,194,195,196],"ESWL","distal ureteric stone","transgluteal","supine ESWL","2023-08-08",{"date":199,"type":36},"2023-08-09",{"date":201,"type":4},"2014-11",{"date":203,"type":22},"2027-11",{"name":42,"class":43},""]